IDEAYA Biosciences' (IDYA) updates from its key early oncology pipeline are supportive, and the strategy is shaping up well around rational combination opportunities, RBC Capital Markets said in a research report emailed Tuesday.
The company's IDE892 candidate showed a favorable safety profile and could be the most efficacious in combination regimens, the brokerage said, adding that it maintained its 2035 revenue guidance for the drug at $1.1 billion.
The company reaffirmed high expectations for the IDE892 and IDE397 regimen amid ongoing dose escalation, with potential expansion in H1 2027 in methylthioadenosine phosphorylase-deletions non-small cell lung cancer, according to the note.
The company's IDE101 and IDE574 candidates were portrayed as complementary approaches to targeting KRAS-driven tumors, analysts wrote.
The brokerage maintained its outperform rating on the stock and price target of $45 per share.
Price: 27.03, Change: -3.33, Percent Change: -10.97
Comments